STATEN
ISLAND, N.Y., Jan. 23,
2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.
("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage
biopharmaceutical company developing a new class of small molecule
antibiotics for difficult-to-treat bacterial infections,
today announced that David P.
Luci, President & Chief Executive Officer, will be
presenting at The Microcap Conference, which will take place
January 30, 2024-February 1, 2024 at the Ceasars Atlantic City
Hotel & Casino in Atlantic City, New Jersey.
Presentation Details:
Wednesday, January 31st,
2 pm ET and
Thursday, February
1st at 11:40 am
ET
Interested parties can register to attend here.
About Acurx Pharmaceuticals, Inc.
Acurx
Pharmaceuticals is a late-stage biopharmaceutical company focused
on developing a new class of small molecule antibiotics for
difficult-to-treat bacterial infections. The Company's approach is
to develop antibiotic candidates with a Gram-positive selective
spectrum (GPSS®) that blocks the active site of the
Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC),
inhibiting DNA replication and leading to Gram-positive bacterial
cell death. Its R&D pipeline includes
antibiotic product candidates that target Gram-positive bacteria,
including Clostridioides difficile, methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus
(VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about
Acurx Pharmaceuticals and its product
pipeline, please visit www.acurxpharma.com
Forward-Looking Statements
Any statements in this
press release about our future expectations, plans and prospects,
including statements regarding our strategy, future operations,
prospects, plans and objectives, and other statements containing
the words "believes," "anticipates," "plans,"
"expects," and similar expressions, constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: whether ibezapolstat will benefit from the QIDP
designation; whether ibezapolstat will advance through the clinical
trial process on a timely basis; whether the results of the
clinical trials of ibezapolstat will warrant the submission of
applications for marketing approval, and if so, whether
ibezapolstat will receive approval from the FDA or equivalent
foreign regulatory agencies where approval is sought; whether, if
ibezapolstat obtains approval, it will be successfully distributed
and marketed; and other risks and uncertainties described in the
Company's annual report filed with the Securities and Exchange
Commission on Form 10-K for the year ended December 31, 2022, and in the
Company's subsequent filings with the Securities and Exchange Commission. Such forward-
looking statements speak only as of the date of this press release,
and Acurx disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances after
the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533
1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-microcap-conference-january-31-2024---february-1-2024-302041587.html
SOURCE Acurx Pharmaceuticals, Inc.